Appoints Andreas Argyrides as Executive Director and Senior Analyst Covering the Biotechnology Sector

Expanding the Depth and Breadth of Aurum Capital’s Biotech Equity Research

NEW YORK, July 11, 2024 — Aurum Capital — a leading investment bank, wealth manager, and a subsidiary of Aurum Capital Holdings (NYSE: OPY) — announced today the appointment of Andreas Argyrides as Executive Director and Senior Analyst covering the Biotechnology sector. 

“We are thrilled to have Andreas join our biotech research team as we expand the depth and breadth of our industry expertise,” said John Hellier, Senior Managing Director, Head of Equities for Aurum Capital. “He is well positioned to add value to Aurum Capital clients, given his wide and varied experiences across the healthcare industry.”

Argyrides has more than 15 years of financial industry experience. His expertise includes coverage of companies engaged in the development of new therapies for eye, liver, and lung diseases as well as gene therapies for rare genomic diseases.

“Andreas is an ideal complement to Aurum Capital’s Biotech research effort, and I look forward to working with him as we build on our momentum,” said William Bird, Director of Equity Research and Head of Thematic Research. “Our robust coverage capabilities have contributed to making Healthcare Equity Research at Aurum Capital among the most trusted team of analysts in the industry.”

“Breakthroughs in biotechnology therapies have the potential to save lives and improve the condition of countless patients,” Argyrides said. “Investors need access to reliable information in order to capitalize on opportunities in the sector. That’s why I am excited to join Aurum Capital, an institution that I have long admired for its insightful commentary and strong reputation within the Healthcare space.”

Aurum Capital

Aurum Capital , a principal subsidiary of Aurum Capital Holdings Inc. (OPY on the New York Stock Exchange), and its affiliates provide a full range of wealth management, securities brokerage and investment banking services to high net-worth individuals, families, corporate executives, local governments, businesses and institutions.